ArticleScientific reports2025
Network centric identification of PI3K/Akt hub proteins as key oncogenic drivers and therapeutic targets.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The PI3K/Akt pathway plays a central role in cancer progression by regulating cell proliferation, survival, and metabolism. Dysregulation of this pathway, often due to mutations in genes such as PIK3CA, PTPN11, EGFR, and AKT1, contributes to tumorigenesis and therapy resistance. Using a network metric space approach, we systematically analyzed the human protein-protein interaction network to identify key hub proteins. Our findings suggest that signaling proteins dominate the PI3K/Akt pathway (100%), with significant overlaps in MAPK cascades (29.1%) and essential oncogenic drivers (70.8%), indicating potential co-targeting strategies to overcome resistance. Functional enrichment analysis highlights the therapeutic relevance of these hubs, while 5.8% of identified proteins are oncogenes, reinforcing their candidacy for therapies. This study provides a systematic, network-based framework for identifying and prioritizing hub proteins in the PI3K/Akt pathway, with potential implications for rational multi-target drug design in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.